Drugs / MOBINITINIB
MOBINITINIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04581512 | Nov 2020 → Dec 2027 expected | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Ellipses Pharma | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOBINITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2207503 ↗ |
| Known as | CCT-241736 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2207503 ↗ |
| Known as | EP0042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04581512 ↗ |
| Modality | Small molecule | — CHEMBL2207503 ↗ |
| Route | Oral | “EP0042 Oral 20 mg 50 mg capsules” NCT04581512 ↗ |